1. Home
  2. MFA vs SPRY Comparison

MFA vs SPRY Comparison

Compare MFA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFA Financial Inc.

MFA

MFA Financial Inc.

N/A

Current Price

$9.67

Market Cap

976.0M

Sector

Real Estate

ML Signal

N/A

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

N/A

Current Price

$10.26

Market Cap

946.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MFA
SPRY
Founded
1997
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
976.0M
946.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MFA
SPRY
Price
$9.67
$10.26
Analyst Decision
Buy
Strong Buy
Analyst Count
7
4
Target Price
$10.96
$31.25
AVG Volume (30 Days)
1.1M
2.1M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
15.17%
N/A
EPS Growth
N/A
N/A
EPS
0.86
N/A
Revenue
$279,011,000.00
$142,772,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$14.85
$124.59
P/E Ratio
$11.04
N/A
Revenue Growth
N/A
5459.66
52 Week Low
$7.85
$6.66
52 Week High
$11.08
$18.90

Technical Indicators

Market Signals
Indicator
MFA
SPRY
Relative Strength Index (RSI) 59.24 56.11
Support Level $9.48 $10.02
Resistance Level $9.72 $11.45
Average True Range (ATR) 0.14 0.60
MACD 0.00 0.13
Stochastic Oscillator 70.00 51.03

Price Performance

Historical Comparison
MFA
SPRY

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: